Promoter holding
64.27%
BE
Biological E. Limited - Due diligence report
A 360° intelligence report on Biological E.: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Biological E. — 360° Intelligence Report
Generated from MCA filings & public records68/100
Trust Score
Moderate
Biological E. is assessed as Moderate with a Trust Score of 68/100. Biological E. is an active public limited indian non-government company incorporated in 1953, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 20 Jun 2026 from the latest processed filings. Biological E. Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
68/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
30/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 70/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A).
Charges position: 14 open (2,580.52 cr) · 70 satisfied (3,316.04 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Sbicap Trustee Company Limited | 5 | 48.0 cr |
| Others | 2 | 48.0 cr |
| State Bank Of India | 3 | 48.0 cr |
| Hdfc Bank Limited | 2 | 48.0 cr |
| Axis Bank Limited | 4 | 48.0 cr |
| Icici Bank Limited | 3 | 48.0 cr |
Compliance Score: 30/100 Caution Indicated
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Flagged by authority: EPFO.
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
- 24 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| NARSING RAO SINGAYAPALLY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PETER BARON PIOT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RUDARAJU ANAND KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| IPPAGUNTA YASODHARA RAMA KRISHNA RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MAHIMA DATLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NARENDER DEV MANTENA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATA SUBBARAJU PENMETSA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| INDIRA SMRITI RAJUPUSAPATI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANTENA PURNIMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Ria Ashok Punyani | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 10 directors on the board.
- No disqualified or deactivated DINs.
- 3 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
4
Group entities
4
Capital events
0 allotment(s) · 1 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| B E Vaccines Pte Ltd | Subsidiary Company | 74.00% |
| B.e. Investment And Finance Pvt Ltd | Subsidiary Company | 74.00% |
| Be Pharma Ceuticals Ag Zug, Switzerland | Subsidiary Company | 74.00% |
| Be Pharmaceuticals Private Limited | Subsidiary Company | 74.00% |
| Biotech Medicals Private Limited | Subsidiary Company | 74.00% |
| Vaxenic India Private Limited | Subsidiary Company | 74.00% |
Key managerial personnel: RUDARAJU ANAND KUMAR (Whole-time director) · MAHIMA DATLA (Managing Director) · NARENDER DEV MANTENA (Whole-time director) · INDIRA SMRITI RAJUPUSAPATI (Whole-time director) · MANTENA PURNIMA (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Net margin improved to 24%.
Operating for 72+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Compliance score is weak (30/100).
14 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 46.35 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence55/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment63/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 14 open charge(s) of 2,580.52 cr already registered.
- Compliance gaps should be priced into terms.
Investor view75/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Dec 2025
Director appointed
Ria Ashok Punyani (Company Secretary)
11 Dec 2024
Charge created
Citi Bank N.A. - 250.00 cr
Charge created
Citi Bank N.A. - 167.80 cr
27 Nov 2024
Director appointed
PETER BARON PIOT (Additional Director)
26 Nov 2024
Director ceased
VENKATA SUBBARAJU PENMETSA
23 Oct 2024
Charge satisfied
Sbicap Trustee Company Limited
07 Oct 2024
Director appointed
NARSING RAO SINGAYAPALLY (Additional Director)
Director appointed
NARENDER DEV MANTENA (Whole-time director)
Director appointed
VENKATA SUBBARAJU PENMETSA (Additional Director)
Director ceased
NARENDER DEV MANTENA
28 Aug 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
30 Mar 2024
Charge satisfied
Others
05 Feb 2024
Charge satisfied
Standard Chartered Bank
20 Dec 2023
Director appointed
INDIRA SMRITI RAJUPUSAPATI (Whole-time director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
10 active director(s) / partner(s); board looks stable and experienced.
24 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 4 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
9 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Honour Lab | U24233TG2011PLC077561 | Shaikpet, Telangana, India |
| Nippon Paint (India) Private Limited | U74999TN2006PTC069356 | Sunguvarchatiram, Tamil Nadu, India |
| Dhampur Bio Organics Limited | L15100UP2020PLC136939 | Sambhal, Uttar Pradesh, India |
| Hflgoa | L15139MH1984PLC316003 | Mumbai, Maharashtra, India |
| Cadila Pharmaceuticals | U24231GJ1991PLC015132 | Ahmedabad, Gujarat, India |
| Amneal Pharmaceuticals | U24231GJ2006PTC048109 | Ahmedabad, Gujarat, India |
| Grindwell Norton | L26593MH1950PLC008163 | Mumbai, Maharashtra, India |
| Gharda Chemicals | U24110MH1967PLC013688 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Biological E. before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Biological E.: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Biological E. - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 68/100, distress signals and MSME payment-delay disclosures - know whether Biological E. pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Biological E. - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Biological E. an active company?
Biological E. has MCA status “Active” with a compliance score of 30/100 (Caution Indicated).
Is Biological E. financially healthy?
Biological E. has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Biological E.?
Its overall Trust Score is 68/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Biological E.?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 10 active director(s) are on record.
Does Biological E. have loans or charges against its assets?
14 open charge(s) are registered against its assets, and 70 earlier charge(s) stand satisfied.
Is Biological E. up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 30/100 (Caution Indicated).
Is it risky to lend to Biological E.?
Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
